In particular, the development of T-DXd for HER2 is leading the way, and we recently demonstrated its efficacy in HER2-expressing uterine carcinosarcoma in both an investigator-initiated phase II clinical trial and a co-clinical study using a PDX model [10]. Here, ERBB2 is linked to uterine carcinosarcoma.